Tango Therapeutics Q3 EPS $(0.23) Beats $(0.34) Estimate, Sales $10.73M Beat $7.32M Estimate
Portfolio Pulse from Benzinga Newsdesk
Tango Therapeutics (NASDAQ:TNGX) reported Q3 losses of $(0.23) per share, beating the analyst consensus estimate of $(0.34) by 32.35%. The company's quarterly sales were $10.73 million, surpassing the analyst consensus estimate of $7.32 million by 46.61%. This represents a 55.09% increase over sales from the same period last year.
November 08, 2023 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tango Therapeutics reported better than expected Q3 results, with losses and sales beating analyst estimates.
Tango Therapeutics reported Q3 losses of $(0.23) per share, which is better than the analyst consensus estimate of $(0.34). This indicates that the company is performing better than expected, which could lead to a positive impact on the stock price in the short term. Additionally, the company's sales also beat estimates, further strengthening the positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100